Stay updated on Tisagenlecleucel in HR B-ALL Clinical Trial
Sign up to get notified when there's something new on the Tisagenlecleucel in HR B-ALL Clinical Trial page.

Latest updates to the Tisagenlecleucel in HR B-ALL Clinical Trial page
- Check6 days agoChange DetectedAdditions include 2026-08-19, 2017 (NIH Grant/Contract), 2023 (NIH Grant/Contract), and 2027-10-19; deletions remove 2027-11-02 and 2026-08-17. These changes reflect updates to funding references and study timeline metadata on the page.SummaryDifference0.3%

- Check13 days agoChange DetectedAdded EU registry identifier 2023-508081-15-00 and updated location entries (New York, NY 10032; Gothenburg 416 85). Also introduced and clarified definitions for disease-free survival and pharmacokinetic measures (Cmax, Tmax) in the study text.SummaryDifference0.6%

- Check20 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 on the page. This reflects a minor maintenance version and does not alter the study details.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe page's Revision label was updated from v3.6.3 to v3.6.4, indicating a small update to the page's versioning.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page footer now displays a new site revision label (v3.6.3) replacing the previous v3.6.2, signaling a platform update. It is a technical change rather than a modification to study information.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.6.2 is displayed on the page, indicating a software release update. No study content or data appear to be altered by this change.SummaryDifference0.0%

Stay in the know with updates to Tisagenlecleucel in HR B-ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tisagenlecleucel in HR B-ALL Clinical Trial page.